Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

In this randomized phase 3 trial, ceftazidime-avibactam plus metronidazole was noninferior to meropenem in treating complicated intra-abdominal infection, with similar efficacy against ceftazidime-resistant and ceftazidime-susceptible pathogens and no new safety concerns observed.

• Publication year

  2016

• Venue

  Clinical Infectious Diseases

• Publication date

  2016-03-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/ciw133PMID 26962078PMCID 4872289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics and tolerability of NXL 104 in normal subjects and in patients with varying degrees of renal insufficiency

  2016cited by this paper
• Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

  2015cited by this paper
• Guidelines for management of intra- abdominal infections

  2015cited by this paper
• Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study

  2014cited by this paper
• Multicenter, Double-Blind, Randomized, Phase II Trial To Assess the Safety and Efficacy of Ceftolozane-Tazobactam plus Metronidazole Compared with Meropenem in Adult Patients with Complicated Intra-Abdominal Infections

  2014cited by this paper
• Source control review in clinical trials of anti-infective agents in complicated intra-abdominal infections.

  2013cited by this paper
• Current strategies for the treatment of complicated intraabdominal infections

  2013cited by this paper
• 2013 WSES guidelines for management of intra-abdominal infections

  2013cited by this paper
• Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial.

  2013cited by this paper
• Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients

  2013cited by this paper
• Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

  2012cited by this paper
• Comparative In Vitro and In Vivo Efficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

  2012cited by this paper
• In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.

  2012cited by this paper
• The emerging NDM carbapenemases.

  2011cited by this paper
• Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

  2011cited by this paper
• Three Decades of β-Lactamase Inhibitors

  2010cited by this paper
• Mechanistic Studies of the Inactivation of TEM-1 and P99 by NXL104, a Novel Non-β-Lactam β-Lactamase Inhibitor

  2010cited by this paper
• Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.

  2008cited by this paper
• NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases.

  2008cited by this paper
• Interval estimation for the difference between independent proportions: comparison of eleven methods.

  1998cited by this paper
• Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease

  1993cited by this paper
• Comparative analysis of two rates.

  1985cited by this paper
• Pharmacokinetics of ceftazidime in patients with renal insufficiency

  1984cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• In vivo evolution of resistance to contemporary β-lactam/β-lactamase inhibitor combinations during treatment of a KPC-producing Serratia marcescens infection

  2026cites this paper
• Real-world usage, effectiveness, and microbiological features of ceftazidime-avibactam in clinical practice in China

  2026cites this paper
• Real-World Evidence and Multidrug Resistant Infections: How Can We Leverage RWE to Improve Patient Outcome with the Novel Beta-Lactam and Beta-Lactam/Beta-Lactamase Inhibitor Combinations

  2026cites this paper
• Clinical pharmacist-led problem-specific education as a strategy for addressing suboptimal antimicrobial use in intensive care unit: a prospective pre-post analysis

  2025cites this paper
• In reply to the Letter to Editor regarding 'Renal function and its impact on the concentration of ceftazidime-avibactam: A cross-sectional study'.

  2025cites this paper
• Ceftazidime/Avibactam Monotherapy Versus Other Antibiotics: Where Do We Stand?

  2025cites this paper
• Continuous infusion versus intermittent dosing of ceftazidime/avibactam in critically ill patients with Klebsiella pneumoniae OXA-48 or Pseudomonas aeruginosa infections: a single-center randomized open-label trial (ZAVICONT). Rationale and design

  2025cites this paper
• Enhanced Outcomes in Bacteremia Through Rapid Phenotype Identification of Carbapenemase-Producing Organisms.

  2025cites this paper
• Revitalizing cephalosporins: The promise of β-lactamase inhibitor combinations

  2025cites this paper
• Controversies in nosocomial peritonitis

  2025influential citation
• Impact of ceftazidime–avibactam on mortality in bloodstream infections: a cohort study in patients with acute leukemia

  2025cites this paper
• Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: a Phase 4, multi-centre, open-label study.

  2025cites this paper
• Difficult-to-Treat Pseudomonas aeruginosa Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal

  2025cites this paper
• Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis

  2025cites this paper
• Personalized Approaches to Patients with Intra-Abdominal Infections

  2025cites this paper
• Cost-Effectiveness Analysis of Ceftazidime-Avibactam and Meropenem in the Treatment of Complex Abdominal Infection in Adults

  2025cites this paper
• Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections

  2025influential citation
• The Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem for Intra-abdominal Infections: A Systematic Review and Meta-Analysis

  2025influential citation
• Antimicrobial Resistance and Mortality in Carbapenem-Resistant Pseudomonas aeruginosa Infections in Southern Thailand

  2025cites this paper
• Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review

  2025cites this paper
• In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania

  2025cites this paper
• Nafithromycin in CABP: promise and precaution—authors’ reply

  2025cites this paper
• An update on antimicrobial selection and duration for intra-abdominal infections

  2025cites this paper
• Reserve antibiotics: overcoming limitations of evidence generated from regulatory approval trials

  2025cites this paper
• Sodium load of novel antibiotics: considerations for nephrologists and clinicians.

  2025cites this paper
• Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial

  2025cites this paper
• Model-informed individualized administration of ceftazidime-avibactam in critically ill patients: population pharmacokinetics studies and a parametric time-to-event analysis.

  2025cites this paper
• Assessment of clinical effectiveness and safety of ceftazidime-avibactam in -treating multi-drug-resistant infections - A retrospective analysis at a tertiary care hospital in Saudi Arabia.

  2025cites this paper
• Finding value in novel antibiotics: How can infectious diseases adopt incremental cost-effectiveness to improve new antibiotic utilization?

  2024cites this paper
• Impact of renal-adjusted ceftazidime/avibactam in patients with KPC-producing Klebsiella pneumoniae bloodstream infection: a retrospective cohort study

  2024cites this paper
• Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery

  2024cites this paper
• Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis

  2024cites this paper
• Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies

  2024cites this paper
• Ceftazidime-avibactam versus other antimicrobial agents for treatment of Multidrug-resistant Pseudomonas aeruginosa: a systematic review and meta-analysis

  2024cites this paper
• Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study

  2024cites this paper
• The burden of antibiotic resistance of the main microorganisms causing infections in humans – review of the literature

  2024cites this paper
• Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.

  2024cites this paper
• Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review

  2024cites this paper
• Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward.

  2024cites this paper
• Managing Antimicrobial Resistance in the Emergency Department.

  2024cites this paper
• Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study

  2024cites this paper
• Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.

  2024cites this paper
• Effectiveness of novel β-lactams for Pseudomonas aeruginosa infection: A systematic review and meta-analysis.

  2024cites this paper
• Ceftazidime/avibactam versus polymyxin B in carbapenem-resistant Klebsiella pneumoniae infections: a propensity score-matched multicenter real-world study

  2024cites this paper
• Estimating the value of new antibiotic treatment strategies in Zhejiang province, China: cost-effectiveness analysis based on a validated dynamic model

  2024cites this paper
• Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections

  2024cites this paper
• Treatment of infections caused by multidrug-resistant Gram-negative bacilli: a practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.

  2024cites this paper
• Reviewing novel treatment options for carbapenem-resistant Enterobacterales

  2024cites this paper
• Efficacy and safety of ceftazidime-avibactam in combination with metronidazole in Japanese patients with complicated intra-abdominal infection: A phase 3, multicentre, open-label study.

  2024cites this paper
• Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study.

  2024cites this paper
• Effectiveness of Ceftazidime-Avibactam in Gram-Negative Nosocomial Pneumonia: A Real-World Study in India

  2024influential citation
• Effectiveness and safety of cefotaxime combined with avibactam for treating multidrug-resistant E coli infections: A systematic review and meta-analysis

  2024cites this paper
• What is the most effective antibiotic monotherapy for severe Pseudomonas aeruginosa infection? A systematic review and meta-analysis of randomized controlled trials.

  2024cites this paper
• Off-label Use of Ceftazidime/Avibactam in Neonatal Intensive Care Unit: A Real-life Experience and Literature Review

  2024cites this paper
• A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intraabdominal infections.

  2024cites this paper
• Ceftazidime-avibactam induced renal disorders: past and present

  2024cites this paper
• The place of new antibiotics for Gram-negative bacterial infections in intensive care: report of a consensus conference

  2023cites this paper
• Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: A systematic review and meta-analysis of randomized controlled trials.

  2023cites this paper
• Bloodstream Infection and Gram-Negative Resistance: The Role for Newer Antibiotics

  2023cites this paper
• Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients

  2023cites this paper
• Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection or complicated urinary tract infection: a network meta-analysis of randomized clinical trials.

  2023cites this paper
• Optimal treatment of ceftazidime-avibactam and aztreonam-avibactam against bloodstream infections or lower respiratory tract infections caused by extensively drug-resistant or pan drug-resistant (XDR/PDR) Pseudomonas aeruginosa

  2023cites this paper
• What to Do with the New Antibiotics?

  2023cites this paper
• The primary pharmacology of ceftazidime/avibactam: microbiology from clinical studies, and development of resistance during treatment.

  2023cites this paper
• Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis

  2023cites this paper
• Cost-Effectiveness of Short Course of Ceftazidime/Avibactam for K. pneumoniae-KPC Bloodstream Infections in Italy

  2023cites this paper
• Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance

  2023cites this paper
• Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.

  2023cites this paper
• Review of novel β‐lactams and β‐lactam/β‐lactamase inhibitor combinations with implications for pediatric use

  2023cites this paper
• Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales

  2023cites this paper
• Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom

  2023cites this paper
• Pharmacokinetic/Pharmacodynamic Target Attainment of Ceftazidime in Adult Patients on General Wards with Different Degrees of Renal Function: A Prospective Observational Bicenter Cohort Study

  2023cites this paper
• Use of Ceftazidime-Avibactam in the Treatment of Clinical Syndromes With Limited Treatment Options: A Retrospective Study

  2023cites this paper
• Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams

  2023cites this paper
• Optimized Treatment of Nosocomial Peritonitis

  2023cites this paper
• The expert clinical pharmacological advice program for tailoring on real-time antimicrobial therapies with emerging TDM candidates in special populations: how the ugly duckling turned into a swan

  2023cites this paper
• Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment of Klebsiella pneumoniae Infection: A Retrospective Analysis from a Hospital in China

  2023cites this paper
• Clinical outcomes of intensive care unit patients infected with multidrug-resistant gram-negative bacteria treated with ceftazidime/avibactam and ceftolozane/tazobactam

  2023cites this paper
• Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion

  2023cites this paper
• In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.

  2023cites this paper
• Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China.

  2023cites this paper
• Ceftazidime-avibactam alone or in combination with Aztreonam versus Polymyxins in the management of carbapenem-Resistant Klebsiella pneumoniae nosocomial Infections (CAPRI study): a retrospective cohort study from South India

  2023cites this paper
• Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme

  2023cites this paper
• The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

  2023cites this paper
• The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings

  2022cites this paper
• IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AGAINST GRAM-NEGATIVE STRAINS IN COLOMBIA 2014-2018.

  2022cites this paper
• Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study).

  2022cites this paper
• The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations

  2022cites this paper
• Peritonitis secundarias del adulto

  2022cites this paper
• Peritoniti secondarie negli adulti

  2022cites this paper
• Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program

  2022cites this paper
• Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

  2022cites this paper
• Carbapenemase-producing Enterobacterales infections: Recent advances in diagnosis and treatment.

  2022cites this paper
• Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.

  2022influential citation
• Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.

  2022cites this paper
• Urgent need for novel antibiotics in Republic of Korea to combat multidrug-resistant bacteria

  2022cites this paper
• Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study

  2022cites this paper
• 头孢他啶阿维巴坦治疗血液病患者粒细胞缺乏期感染的疗效分析

  2022cites this paper
• Antimicrobial resistance in Gram-negative bacilli in Spain: an experts’ view

  2022cites this paper
• Beta-lactam beta-lactamase inhibitors

  2022cites this paper